Metaplastic carcinoma of the breast : Prognosis and response to systemic treatment in metastatic disease

Show full item record



Permalink

http://hdl.handle.net/10138/312896

Citation

Takala , S , Heikkilä , P , Nevanlinna , H , Blomqvist , C & Mattson , J 2019 , ' Metaplastic carcinoma of the breast : Prognosis and response to systemic treatment in metastatic disease ' , Breast Journal , vol. 25 , no. 3 , pp. 418-424 . https://doi.org/10.1111/tbj.13234

Title: Metaplastic carcinoma of the breast : Prognosis and response to systemic treatment in metastatic disease
Author: Takala, Sari; Heikkilä, Päivi; Nevanlinna, Heli; Blomqvist, Carl; Mattson, Johanna
Contributor organization: Department of Oncology
HUS Comprehensive Cancer Center
HUSLAB
Department of Pathology
Department of Obstetrics and Gynecology
HUS Gynecology and Obstetrics
Clinicum
University Management
Date: 2019
Language: eng
Number of pages: 7
Belongs to series: Breast Journal
ISSN: 1075-122X
DOI: https://doi.org/10.1111/tbj.13234
URI: http://hdl.handle.net/10138/312896
Abstract: Background: Metaplastic breast carcinomas (MpBCs) are rare, aggressive breast cancers. Due to the scant literature of this disease most guidelines do not give recommendation for this entity. The aim of the study was to review the clinicopathologic features, treatment, and outcomes of the patients with MpBC treated at our institution. Material and methods: We searched databases for patients with histologically confirmed MpBC from 2002 to 2016. Results: A total of 78 patients with MpBC were included in the study. All histological material was reviewed by an experienced breast pathologist. Most tumors were grade 3 (83%) and triple negative (85%). Eighty-two percent were node negative. Sixty-four percent received adjuvant chemotherapy. The 5-year disease free survival was 63% and 5-year breast cancer specific overall survival was 61%. Tumor size and mixed metaplastic histology were associated with worse outcome in this patient group. One third of the patients (n = 28) had metastatic disease at initial presentation or developed metastases at follow-up. The lungs were the most common site of first distant recurrence. Half (n = 14) of these patients received palliative chemotherapy. Of those only 6% (n = 2) had partial response and 18% had stable disease as best response to treatment. The median overall survival time with metastatic disease was only 3.4 months. Conclusion: MpBC is an aggressive type of breast cancer with poor outcome despite low nodal involvement and aggressive local and systemic therapy. Tumor response to palliative systemic chemotherapy remains poor for MpBC patients.
Subject: chemotherapy
metaplastic breast cancer
metastatic breast cancer
prognostic factors
systemic treatment
CLINICOPATHOLOGICAL FEATURES
SARCOMATOID CARCINOMA
CANCER
3122 Cancers
3123 Gynaecology and paediatrics
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: draft


Files in this item

Total number of downloads: Loading...

Files Size Format View
Metaplastic_car ... _in_metastatic_disease.pdf 408.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record